239 related articles for article (PubMed ID: 32089012)
1. Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives.
Boutou AK; Pitsiou G
Expert Opin Pharmacother; 2020 Jul; 21(10):1145-1155. PubMed ID: 32089012
[TBL] [Abstract][Full Text] [Related]
2. Riociguat for the treatment of pulmonary hypertension.
Meis T; Behr J
Expert Opin Pharmacother; 2014 Nov; 15(16):2419-27. PubMed ID: 25260791
[TBL] [Abstract][Full Text] [Related]
3. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
4. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
[TBL] [Abstract][Full Text] [Related]
5. Riociguat: a review of its use in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension.
Garnock-Jones KP
Drugs; 2014 Nov; 74(17):2065-78. PubMed ID: 25352393
[TBL] [Abstract][Full Text] [Related]
6. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
7. Riociguat: a novel therapeutic option for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Mielniczuk LM; Swiston JR; Mehta S
Can J Cardiol; 2014 Oct; 30(10):1233-40. PubMed ID: 25154043
[TBL] [Abstract][Full Text] [Related]
8. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
9. Overview of Riociguat and Its Role in the Treatment of Pulmonary Hypertension.
Kenny M; Clarke MM; Pogue KT
J Pharm Pract; 2022 Jun; 35(3):437-444. PubMed ID: 33084500
[TBL] [Abstract][Full Text] [Related]
10. [The achievements of the modern specific therapy of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: focus on the stimulator of soluble guanylate cyclase riociguat].
Gratsianskaya SE; Valieva ZS; Martynyuk TV
Ter Arkh; 2020 Oct; 92(9):77-84. PubMed ID: 33346435
[TBL] [Abstract][Full Text] [Related]
11. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
12. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
[TBL] [Abstract][Full Text] [Related]
13. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
14. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
15. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension?
Kim NH
Eur Respir Rev; 2010 Mar; 19(115):68-71. PubMed ID: 20956169
[TBL] [Abstract][Full Text] [Related]
16. Riociguat for the treatment of pulmonary hypertension.
Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
[TBL] [Abstract][Full Text] [Related]
17. Riociguat: Clinical research and evolving role in therapy.
Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
[TBL] [Abstract][Full Text] [Related]
18. Guanylate cyclase stimulators for pulmonary hypertension.
Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
[TBL] [Abstract][Full Text] [Related]
19. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
DeSouza SA; Preston IR
Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
[TBL] [Abstract][Full Text] [Related]
20. [Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].
Leuchte HH; Behr J; Ewert R; Ghofrani HA; Grünig E; Halank M; Held M; Klose H; Rosenkranz S; Schermuly RT; Wilkens H; Hoeper MM
Pneumologie; 2015 Mar; 69(3):135-43. PubMed ID: 25750094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
